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we observed the formation of a new tissue with some features 
of hyaline cartilage either for the presence of collagen type II ex- 
pression or the morphological appearance. We could observe the 
spatial distribution of collagen fibres according to Benningoff's 
scheme. 
Conclusion: These preliminary data indicate that HILT was able 
to induce a physiological repair of deep and severe osteochon- 
dral lesions in an animal model. The quality of the newly formed 
tissue was excellent in terms of shape and morphological distri- 
bution of isogenic groups, type and spatial distribution of collagen 
fibres and physical-chemical composition of extracellular matrix. 
Moreover, the centripetal growth of cartilage, from edges to the 
central areas of the created lesions, suggest that the proliferation 
of chondrocytes is faster than the proliferation of mesenchymal 
cells of the subchondral bone. These results advocate the use 
of HILT treatment for further in vivo studies and finally, in human 
clinical trials for the treatment of knee cartilage defects. 
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Introduction: Substance P (SP) is a neuropeptide found at in- 
creased concentrations in inflamed joints and believed to play 
a key role in joint pain and pathology. Sensory nerve termi- 
nals containing SP have been identified in the synovium, liga- 
ments, tendons, menisci and the osteochondral junction in os- 
teoarthritic joints. Recent studies have also shown that chon- 
drocytes express SP receptors, however, the mechanism of SP 
action on chondrocytes remains unknown. Chondrocytes exhibit 
large (greater than 100 mS/F) voltage-gated potassium currents 
(Kv), and studies in nerve and muscle show these to be a poten- 
tial target for SP modulation. 
Aim of Study: In the present study electrophysiology was used 
to determine the effects of SP on potassium currents in equine 
articular chondrocytes. 
Methods: We used whole-cell patch-clamp recording from first- 
expansion and first-passage equine chondrocyte in conventional 
physiological solutions. 
Results: We found equine articular chondrocyte Kv currents to 
be insensitive to dendrotoxin-I, but blocked by both tetraethylam- 
monium and 4-aminopyridine (2.64-0.6mM (n=6) and1.34-0.7 mM 
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Fig. 1. Histogram of chondrocyte Kv currents produced following application 
of 4-aminopyridine, dendrotoxin-I and SP relative to untreated cells (control), 
all at +40mV. 
(n= 5) respectively). Interestingly SP positively modulated equine 
chondrocyte Kv: addition of II~M SP caused a statistically signif- 
icant* (approximately 100%) increase in whole-cell conductance 
at +40mV (p _<0.005, 2-way ANOVA test, n=4) (Fig. 1). Following 
Boltzmann fitting of the data, comparison of V l /2  and k param- 
eters yielded a significant increase in k (p_<0.005, paired t-test, 
n=4) compared with control recordings from the same cell, but no 
significant change in Vl/2. 
Conclusions: To our knowledge, this is the first study of the ef- 
fects of SP on Kv in equine articular chondrocytes. Future studies 
will determine the mechanisms and receptor specificity of this ef- 
fect. 
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Aim of Study: Data on the burden of disease in hand osteoarthri- 
tis (OA) are limited. The objective of the present study was to as- 
sess the disease burden of patients with OA by comparing their 
SF-36 scores with the scores of patients with rheumatoid arthri- 
tis (RA), healthy controls and general population scores and by 
computation of s-scores which allow for comparisons across the 
different SF-36 scales. 
Methods: Female patients between 50 and 70 years of age with 
hand OA (n = 190) and RA (n = 194), referred to our rheumatol- 
ogy department within the preceding two years and healthy con- 
trols (n=144) underwent a thorough clinical examination includ- 
ing completion of the SF-36. The OA and RA patients and the 
controls were compared by their SF- 36 mean scores and also 
by comparing all three groups with normative SF-36 data from an 
age-matched cohort of women representative for the general Nor- 
wegian population. Mean (SD) age in the OA/RA/control groups 
was 61.6 (5.6)/61.1 (6.0)/60.8 (5.7) years, mean age of the gen- 
eral population was 59.2 (6.1). Comparisons were done by one- 
way ANOVA with Tukey post hoc test. Standard difference scores 
(s-scores) to assess the burden of disease were computed by 
subtracting the mean scores of the general population from the 
mean scores of the patients and controls followed by dividing 
these deviations by each scale's standard deviation in the gen- 
eral population. 
Results: Healthy controls had similar scores as the general pop- 
ulation, i.e. s-scores around 0. OA patients had especially re- 
duced health related quality of life in the area of pain, vitality 
and mental health, whereas RA patients especially had deficits 
in physical functioning. 
Table 1. SF-36 scores and s-scores for comparison with general population 
SF-36 scales 
Mean scores S-scores 
OA RA Controls OA RA Controls 
Physical function 57.6 48.4 82.6 -1.35 -1.82 -0.05 
Pain 39.6 44.1 70.9 -1.17 -1.01 -0.03 
General health 51.5 47.5 70.6 -0.90 -1.07 -0.12 
Vitality 40.0 43.3 61.1 -0.91 -0.76 0.07 
Social functioning 67.4 69.2 83.1 -0.77 -0.69 -0.07 
Mental health 68.1 73.3 80.1 -0.58 -0.29 0.09 
Conclusions: Both OA and RA patients experience major impact 
on the subjective health status by their disease as compared to 
healthy controls and general population norms. The consistency 
of the differences between the two patients groups and the two 
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comparison groups strengthen the robustness of the findings and 
indicate a similar disease burden of OA and RA. 
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Aim of study: As calcitonin (CT) reduces the severity of cartilage 
lesions and prevents the net loss of collagen, hyaluronan and ag- 
grecan aggregates from the cartilage tissue in canine experimen- 
tal osteoarthritis (OA), this preliminary, randomized, double blind, 
placebo controlled, parallel study was conducted for 3 months to 
assess the efficacy of a novel oral formulation of CT in patients 
suffering from knee OA. 
Methods: For up to 84 days, patients received daily either a 
placebo (n=16), 0.5 mg CT (n=17) or 1 mg CT (n=18). Clin- 
ical efficacy on pain, function and stiffness was evaluated by 
Lequesne's algofunctional indices (LI). Biochemical parameters 
of joint metabolism, as assessed by enzyme immunoassays, in- 
cluded urinary levels of type I and type II collagen C telopeptide 
(CTX-I and CTX-II, respectively) as well as serum levels of type 
II collagen neoepitope C2C, matrix metalloproteinase (MMP)- 
3, collagenase-3 (MMP-13), tissue inhibitors 1 and 2 of MMPs 
(TIMP-1 and TIMP-2) and hyaluronan (HA). Statistical analysis 
included analysis of variance followed by Tukey test whenever 
needed. 
Results: The number of withdrawals was 2 in the placebo group 
(lack of efficacy), 4 in the 0.5 mg CT group (1 for lack of efficacy 
and 3 for nausea and headache) and 4 in the 1 mg CT group 
(2 for protocol violation and 2 for nausea and headache). In the 
placebo group there was no significant change in the mean 4- SD 
value of LI (from 14.8 4- 2.7 at day 0 to 12 4- 4.3 at day 84). In 
the 2 CT groups, the mean value of LI was similar at day 0 (15.4 
4- 2.6) and was significantly decreased at day 84 (10.6 4- 3.8 in 
the 0.5 mg group and 9.6 4- 3.2 in the 1 mg group). Further, when 
compared to values at study entry, levels of biochemical parame- 
ters had changed significantly in all groups at day 84 (p < 0.05 to 
0.01). In the placebo group, there was a significant increase in the 
mean urinary levels of both CTX-1 (15%) and CTX-II (9%) and in 
the mean serum levels of C2C (29%), MMP-13 (153%), MMP-3 
(49%), and HA (25%). In contrast in the 1 mg CT group, there was 
a significant decrease in the mean urinary levels of both CTX-1 
(10%), CTX-II (21%) as well as in the mean serum levels of C2C 
(25%), MMP-13 (40%), MMP-3 (18%) and HA (28%). Results ob- 
tained in the 0.5 mg CT group were intermediate between the 2 
other groups and are not reported. No change in the mean serum 
levels of TIMP-1 and TIMP-2 was observed in the 3 groups. 
Conclusions: Although the cohort of patients was rather small, 
results of this preliminary study strongly suggest that CT exhibits 
not only clinical efficacy but also reduces markedly the levels 
of several biochemical parameters of joint metabolism which all 
have been shown to have a pejorative prognostic value of the OA 
disease process in longitudinal studies including large cohorts of 
patients. 
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Aim of Study: To confirm the positive effects of Pulsed Signal 
Therapy (PST) for the treatment of osteoarthritis - a prospec- 
tive, double-blind, randomized study in patients with gonarthrosis 
stages I-III, as classified by Altman et aL, and severity as classi- 
fied by Brandt etaL 
Method: 2 Groups: 
• PST-treated group and placebo group. 
• Each patient was randomized into either the placebo or treat- 
ment group using envelopes, each containing 4 identical smart 
cards (chipcards). The only distinction between the cards was 
the serial number. Two were active and two placebo. 
Treatment: A pulsed signal carried on an electromagnetic wave is 
delivered from a medical device, to target the affected tissue by 
direct induction. PST-technology utilizes direct current and pro- 
duces a quasi-rectangular waveform with a field strength of 12.5 
G and a frequency of 1-30 Hz. The frequency is pulse modulated 
and implementation is by a free-wheeling diode. The generated 
pulsed signal, of specific energy parameters, stimulates the re- 
pair and restoration of damaged cartilage tissue, and accelerates 
healing, by mimicking the innate streaming potential(s) generated 
during mechanical compression. 
Treatments were administered aily for one-hour, over nine con- 
secutive days, with allowed interruption over the weekend. A 
10cm visual analog scale (VAS) was used to evaluate patients 
before PST treatment (baseline), and at 1-month, 3-months and 
6-months post-treatment. 
Statistical method: The paired T test was used to analyze the 
difference in the mean VAS score at 1-month, 3-months and 6- 
months, compared to baseline. Significant esting was two tailed, 
with p<0.05 accepted as statistically significant. 
Results: 41 patients were randomly recruited into the study - 21 
into the placebo group and 20 into the active group. There were 
no patients lost in the follow-up periods nor were any withdrawn 
from the study. The two groups did not differ significantly with re- 
spect to age, sex, race, body weight or duration of symptoms. 
There were no adverse effects reported by any patients. There 
were no patients who reported using more than their usual medi- 
cation or requiring new medications for their knee pain during the 
study period. 
The mean baseline VAS score of the two groups was not sta- 
tistically different (p=0.82). In the active group, the improvement 
in the VAS score at 1-month, 3-months and 6-months when 
compared to the baseline VAS score was statistically significant 
(p<0.05). The placebo group, however, did not show any statisti- 
cal significance (p>0.05). 
Conclusion: With over 25 clinical studies supported by in vitro 
studies, this prospective double-blind randomized study confirms 
the efficacy of PST for the treatment of osteoarthritis. PST stimu- 
lates the repair and restoration of damaged cartilage tissue, and 
accelerates the healing process. To date, no adverse effects have 
been reported. 
In this study, patients with early gonarthrosis demonstrated a sta- 
tistically significant reduction in pain as measured by VAS, post 
PST-treatment. Pain reduction begins as early as one month and 
lasts for as long as 6 months after treatment. 
